Xencor (NASDAQ:XNCR) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Xencor (NASDAQ:XNCR) in a research note published on Wednesday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $55.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on the stock. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Cantor Fitzgerald lifted their price target on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Royal Bank Of Canada lifted their price target on shares of Xencor from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, September 21st. Finally, Wedbush raised their target price on Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Xencor has an average rating of “Moderate Buy” and an average target price of $34.00.

Xencor Stock Up 0.3%

Shares of XNCR opened at $24.84 on Wednesday. Xencor has a 52-week low of $10.38 and a 52-week high of $30.61. The company has a market capitalization of $1.85 billion, a PE ratio of -11.45 and a beta of 0.89. The stock has a fifty day simple moving average of $24.32 and a two-hundred day simple moving average of $17.09.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The business had revenue of $51.22 million for the quarter, compared to analyst estimates of $18.89 million. During the same quarter in the previous year, the firm earned ($0.41) EPS. The company’s quarterly revenue was up 17.4% compared to the same quarter last year. As a group, equities analysts anticipate that Xencor will post -3.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of XNCR. Allworth Financial LP lifted its position in shares of Xencor by 23.2% during the second quarter. Allworth Financial LP now owns 3,436 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 646 shares in the last quarter. WINTON GROUP Ltd grew its holdings in shares of Xencor by 1.5% in the second quarter. WINTON GROUP Ltd now owns 106,247 shares of the biopharmaceutical company’s stock valued at $1,711,000 after purchasing an additional 1,534 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Xencor in the second quarter valued at approximately $30,000. Diversified Trust Co increased its stake in Xencor by 16.7% during the 1st quarter. Diversified Trust Co now owns 21,528 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 3,086 shares during the period. Finally, Velan Capital Investment Management LP increased its stake in Xencor by 2.0% during the 2nd quarter. Velan Capital Investment Management LP now owns 255,000 shares of the biopharmaceutical company’s stock worth $4,106,000 after buying an additional 5,000 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies and cytokine therapeutics for cancer, autoimmune diseases and other serious medical conditions. The company’s research is based largely on its XmAb technology platform, which is designed to modify antibody structures to improve immune-system activity, extend drug half-life or enable the simultaneous targeting of multiple biological pathways.

Xencor’s pipeline includes investigational therapies intended to engage immune cells, regulate immune responses and target tumor-associated proteins.